Havrilesky L - Search Results

1

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Bixel K, Vetter M, Davidson B, Berchuck A, Cohn D, Copeland L, Fowler JM, Havrilesky L, Lee PS, O'Malley DM, Salani R, Valea F, Alvarez Secord A, Backes F. Bixel K, et al. Among authors: havrilesky l. Gynecol Oncol. 2020 Mar;156(3):530-534. doi: 10.1016/j.ygyno.2019.12.016. Epub 2020 Jan 11. Gynecol Oncol. 2020. PMID: 31937450

2

Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.

Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC Jr, Berchuck A. Havrilesky LJ, et al. Cancer Res. 1995 Feb 15;55(4):944-8. Cancer Res. 1995. PMID: 7531618

3

Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.

Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, Marks JR. Elbendary A, et al. Among authors: havrilesky l. Cell Growth Differ. 1994 Dec;5(12):1301-7. Cell Growth Differ. 1994. PMID: 7696178

4

Chemotherapy-induced apoptosis in epithelial ovarian cancers.

Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC, Berchuck A. Havrilesky LJ, et al. Obstet Gynecol. 1995 Jun;85(6):1007-10. doi: 10.1016/0029-7844(95)00058-y. Obstet Gynecol. 1995. PMID: 7770245

5

Pathogenesis of ovarian cancers.

Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Berchuck A, et al. Among authors: havrilesky l. J Soc Gynecol Investig. 1994 Jul-Sep;1(3):181-90. doi: 10.1177/107155769400100302. J Soc Gynecol Investig. 1994. PMID: 9419769

6

Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.

Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A. Havrilesky LJ, et al. J Soc Gynecol Investig. 2001 Mar-Apr;8(2):104-13. J Soc Gynecol Investig. 2001. PMID: 11336882

7

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Havrilesky LJ, et al. Gynecol Oncol. 2001 Dec;83(3):491-500. doi: 10.1006/gyno.2001.6464. Gynecol Oncol. 2001. PMID: 11733961

8

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.

van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF. van Haaften-Day C, et al. Among authors: havrilesky lj. Cancer. 2001 Dec 1;92(11):2837-44. doi: 10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5. Cancer. 2001. PMID: 11753957

9

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.

Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME. Havrilesky LJ, et al. Gynecol Oncol. 2003 Jan;88(1):51-7. doi: 10.1006/gyno.2002.6859. Gynecol Oncol. 2003. PMID: 12504627 Clinical Trial.

10

The role of PET scanning in the detection of recurrent cervical cancer.

Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. Havrilesky LJ, et al. Gynecol Oncol. 2003 Jul;90(1):186-90. doi: 10.1016/s0090-8258(03)00256-7. Gynecol Oncol. 2003. PMID: 12821362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page